drugset / Trial / NCT03267589
Trial in Patients With Relapsed Ovarian Cancer
Phase 2
Completed
25 enrolled
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGynecologic Cancer Intergroup (GCIG) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The overall objectiv is to obtain preliminary evidence of efficacy of novel agents for the management of relapsed ovarian cancer, and in part 2 efficacy of novel agents compared to the standard of care (SoC).
Timeline
- Start
- 2018-05-14
- Primary completion
- 2021-10-19
- Completion
- 2021-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Oleclumab | Monoclonal antibody | — | — |
| Subject | TAVOLIMAB | Monoclonal antibody | — | — |
| Subject | Tremelilumab | Unknown | — | — |